News Sentiment

DMAC sentiment intelligence

DiaMedica Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.30 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.8% over one week, +24.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend inactive 24.8% over four weeks
Fair value 53.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 35
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
MarketBeat 5
TradingView 5
Business Wire 3
Moomoo 3
MT Newswires 3
TradingKey 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 3
Guidance 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Stock Titan Direct company coverage

New DiaMedica hire gets 160,000 stock options at $7.64

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it granted options to a newly hired non-executive employee to purchase 160,000 shares of common stock. The stock options, with an exercise price of $7.64 per share, were a material inducement for their employment, complyin

Tone
Positive 60/100
Event
Market update
Published
17 Jul 2026 20:10
Source
Stock Titan
Stock Traders Daily Direct company coverage

(DMAC) Risk Channels and Responsive Allocation

Diamedica Therapeutics Inc. (NASDAQ: DMAC) is showing conflicting sentiment across horizons, suggesting choppy conditions. The article highlights an exceptional 79.0:1 risk-reward setup targeting a 21.9% gain versus 0.3% risk. AI models have generated three distinct trading strat

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 07:12
Source
Stock Traders Daily
TradingView Direct company coverage

Enterprise value to revenue forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC

The article discusses the enterprise value to revenue forward for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It highlights financial data available on TradingView, covering various aspects of the company's financial performance.

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 16:12
Source
TradingView
Intellectia AI Direct company coverage

DMAC PE Ratio & Valuation, Is DMAC Overvalued

DiaMedica Therapeutics Inc (DMAC) is currently in the "Fair zone" according to its forward PS ratio, which is 0.00 compared to a five-year average of -4.69. The company's current Price-to-Book (P/B) ratio of 9.14 is significantly higher than its 3-year and 5-year averages, and it

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 02:39
Source
Intellectia AI
TradingView Direct company coverage

Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC

This article provides the enterprise value to EBITDA forward for DiaMedica Therapeutics Inc. (NASDAQ:DMAC). It presents financial data and company overview information sourced from TradingView, FactSet, and other financial data providers.

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 03:47
Source
TradingView
Moomoo Direct company coverage

DiaMedica Therapeutics | 10-Q: Q1 2026 Earnings Report

This document is the official 10-Q filing for DiaMedica Therapeutics, detailing their earnings report for the first quarter of 2026. As a regulatory filing, it provides a comprehensive overview of the company's financial performance and operational activities during that period.

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 03:39
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC

This article section displays the "Price to sales forward" metric for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It indicates that the market was closed at the time of viewing and no trades were recorded for this specific financial data point.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:40
Source
TradingView
TradingView Direct company coverage

DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC)

This article provides an overview of DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock performance, financial estimates, and analyst forecasts. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also includ

Tone
Positive 70/100
Event
Earnings
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

DMAC Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for DiaMedica Therapeutics Inc. (DMAC), detailing analyst opinions, historical price performance, and key financial metrics. It highlights that analysts have a max price estimate of $25.00 and a min estimate of $11.00 for DMAC, wit

Tone
Positive 65/100
Event
Analyst action
Published
25 Jun 2026 21:09
Source
TradingView
MarketBeat Direct company coverage

DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jun 2026

This article provides an update on DiaMedica Therapeutics (DMAC) short interest and short float as of June 15, 2026. DMAC had 4.86 million shares sold short, representing 9.50% of its public float, marking a slight decrease from the previous report. The short interest ratio is 28

Tone
Negative 38/100
Event
Market update
Published
25 Jun 2026 10:41
Source
MarketBeat
The Globe and Mail Direct company coverage

Analysts’ Top Healthcare Picks: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN)

This article highlights bullish analyst ratings for three healthcare companies: Diamedica Therapeutics (DMAC), Guardian Pharmacy Services, Inc. Class A (GRDN), and Eledon Pharmaceuticals (ELDN). Analysts from Lake Street, Bank of America Securities, and Noble Financial reiterate

Tone
Positive 73/100
Event
Analyst action
Published
25 Jun 2026 04:11
Source
The Globe and Mail
Market source Direct company coverage

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

DiaMedica Therapeutics has initiated a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction (FGR), a severe pregnancy complication often leading to stillbirth. The trial will evaluate DM199's safety and efficacy in up to 30 patients with early-onset FGR,

Tone
Positive 71/100
Event
Market update
Published
25 Jun 2026 02:39
Source
Market source
Simply Wall Street Direct company coverage

DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43%

DiaMedica Therapeutics (NASDAQ:DMAC) saw its shares increase by 10% last week, rewarding insiders who had purchased stock in the past year with a 43% gain on their initial investment. The largest insider purchase was made by Thomas von Koch for US$10.0m at US$3.50 per share, sign

Tone
Positive 71/100
Event
Market update
Published
24 Jun 2026 14:12
Source
Simply Wall Street
Investing.com Direct company coverage

DiaMedica doses first patients in fetal growth restriction trial

DiaMedica Therapeutics Inc. has begun dosing patients in a Phase 2 trial for DM199 (rinvecalinase alfa) to treat fetal growth restriction, a condition affecting about 10% of pregnancies with no approved pharmacologic therapies. The trial aims to assess safety and tolerability in

Tone
Positive 66/100
Event
Market update
Published
23 Jun 2026 13:41
Source
Investing.com
TradingKey Direct company coverage

DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of DiaMedica Therapeutics Inc (DMAC)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports "No Data" for both dividend payments and stock splits, indicating a lack o

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 19:40
Source
TradingKey
Moomoo Direct company coverage

Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating

Craig-Hallum has reiterated its Buy rating for DiaMedica Therapeutics (DMAC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.

Tone
Neutral 50/100
Event
Guidance
Published
18 Jun 2026 19:11
Source
Moomoo
TradingKey Direct company coverage

DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for DiaMedica Therapeutics Inc (DMAC), ranking its current earnings forecast score at 8.00 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $13.00 for DMAC, with a consensus "Buy" rating b

Tone
Positive 73/100
Event
Earnings
Published
18 Jun 2026 01:39
Source
TradingKey
TradingKey Direct company coverage

DiaMedica Therapeutics Inc

This article provides an overview of DiaMedica Therapeutics Inc (DMAC), including its current stock price and market capitalization. It indicates that relevant detailed revenue breakdown data by business segment and region has not yet been disclosed by the company. The page serve

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:39
Source
TradingKey
Investing.com Direct company coverage

DiaMedica to conduct rat study addressing FDA data request

DiaMedica Therapeutics Inc. will conduct a rat study to address an FDA request for additional nonclinical reproductive toxicity data for DM199, a treatment for preeclampsia. The company needs to demonstrate sufficient DM199 exposure and enzymatic activity in rats to support their

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 13:40
Source
Investing.com
Business Wire Direct company coverage

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DiaMedica Therapeutics Inc. announced it received FDA feedback on its DM199 preeclampsia nonclinical program, requiring additional reproductive toxicity data. The company plans to conduct a rat pharmacokinetic and activity study to address the FDA's request and support a U.S. inv

Tone
Positive 64/100
Event
Market update
Published
16 Jun 2026 12:40
Source
Business Wire